Insider Selling: Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CAO Sells $10,857.00 in Stock

Share on StockTwits

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) CAO Kelly Macdonald sold 987 shares of the company’s stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $11.00, for a total transaction of $10,857.00. Following the sale, the chief accounting officer now directly owns 78,444 shares of the company’s stock, valued at $862,884. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of IRWD traded up $0.09 during mid-day trading on Friday, reaching $11.69. The stock had a trading volume of 95,251 shares, compared to its average volume of 1,296,772. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -12.31 and a beta of 1.80. Ironwood Pharmaceuticals, Inc. has a 12 month low of $7.91 and a 12 month high of $15.21. The business has a fifty day moving average of $9.40 and a 200 day moving average of $10.07.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last posted its quarterly earnings results on Thursday, October 31st. The biotechnology company reported $0.40 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.30. The business had revenue of $131.17 million during the quarter, compared to analyst estimates of $97.10 million. Ironwood Pharmaceuticals had a negative net margin of 9.67% and a negative return on equity of 15.83%. The company’s revenue was up 99.7% on a year-over-year basis. During the same period in the prior year, the business posted ($0.27) earnings per share. As a group, equities analysts anticipate that Ironwood Pharmaceuticals, Inc. will post 0.49 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of IRWD. Vanguard Group Inc. boosted its position in shares of Ironwood Pharmaceuticals by 4.5% during the second quarter. Vanguard Group Inc. now owns 15,606,157 shares of the biotechnology company’s stock worth $170,730,000 after acquiring an additional 664,893 shares during the last quarter. Brown Capital Management LLC boosted its position in shares of Ironwood Pharmaceuticals by 19.4% during the second quarter. Brown Capital Management LLC now owns 12,329,890 shares of the biotechnology company’s stock worth $134,889,000 after acquiring an additional 2,003,252 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Ironwood Pharmaceuticals by 12.8% during the second quarter. Janus Henderson Group PLC now owns 7,505,293 shares of the biotechnology company’s stock worth $82,108,000 after acquiring an additional 852,356 shares during the last quarter. EcoR1 Capital LLC boosted its position in shares of Ironwood Pharmaceuticals by 6.2% during the second quarter. EcoR1 Capital LLC now owns 4,671,408 shares of the biotechnology company’s stock worth $51,105,000 after acquiring an additional 274,240 shares during the last quarter. Finally, Westfield Capital Management Co. LP boosted its position in shares of Ironwood Pharmaceuticals by 27.1% during the second quarter. Westfield Capital Management Co. LP now owns 2,392,774 shares of the biotechnology company’s stock worth $26,177,000 after acquiring an additional 510,900 shares during the last quarter.

A number of brokerages have commented on IRWD. ValuEngine cut shares of Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Cowen set a $12.00 target price on shares of Ironwood Pharmaceuticals and gave the company a “hold” rating in a report on Friday, September 13th. Wedbush upped their target price on shares of Ironwood Pharmaceuticals from $11.00 to $12.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, BidaskClub raised shares of Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, November 8th. Nine investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Ironwood Pharmaceuticals has an average rating of “Hold” and a consensus price target of $14.50.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; MD-7246, an oral, intestinal, non-opioid, pain-relieving agent for patients suffering from IBS with diarrhea; and IW 3718, a gastric retentive formulation of a bile acid sequestrant, which is in Phase III clinical trials for the treatment of GERD.

Featured Story: Sell-Side Analysts

Insider Buying and Selling by Quarter for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Automotive Finco  Stock Price Down 1.7%
Automotive Finco Stock Price Down 1.7%
X-trackers FTSE Developed ex US Comprehensive Factor ETF  Stock Price Up 0.1%
X-trackers FTSE Developed ex US Comprehensive Factor ETF Stock Price Up 0.1%
Bunker Hill Mining  Stock Price Up 17.7%
Bunker Hill Mining Stock Price Up 17.7%
iPath Series B Bloomberg Natural Gas Subindex Total Return ETN  Trading 0.5% Higher
iPath Series B Bloomberg Natural Gas Subindex Total Return ETN Trading 0.5% Higher
Centrus Energy Corp  Short Interest Update
Centrus Energy Corp Short Interest Update
SandRidge Permian Trust  Short Interest Update
SandRidge Permian Trust Short Interest Update


© 2006-2019 Ticker Report